MORDOVIAN SCIENTISTS DEVELOP TRANSDERMAL PATCH FOR ALLERGY PREVENTION

Mordovian researchers are developing an innovative transdermal patch designed to prevent allergies, offering a convenient and long-lasting alternative to daily oral medications. This drug delivery system allows active ingredients to be absorbed through the skin, ensuring continuous therapeutic support over an extended period.

Currently, transdermal therapeutic systems registered in the Russian State Register of Medicines are primarily used for treating nicotine addiction, arrhythmia, Alzheimer’s disease, and pain management. However, all such products are currently manufactured by foreign companies.

A Breakthrough in Allergy Treatment

«The key advantage of a transdermal drug delivery system is its prolonged effect, maintaining a steady concentration of the active substance in the bloodstream. By eliminating the need for daily pill intake, this system is particularly beneficial for allergy sufferers during seasonal pollen outbreaks. With its extended-release mechanism, a single patch could replace an entire course of allergy tablets,» explained Dr. Nikolai Pyataev, Director of the Federal Center for Biotechnology and Medicine Development at Ogarev Mordovia State University.

The waterproof patch is designed for long-lasting use, requiring replacement only once a week. The active ingredient will be available over the counter, and its cost is expected to be comparable to that of an equivalent tablet-based treatment.

Advancing Towards Market Launch

Researchers have identified a preliminary formulation and are currently conducting tests on laboratory animals while refining its properties. Before entering the pharmaceutical market, the product must undergo preclinical and clinical trials. The launch of production is scheduled for 2025.

Strategic Development in Biotechnology

«The collaboration between academia and industry in drug development is a crucial step for advancing the pharmaceutical sector at both regional and national levels. In 2024, with funding from the ‘Priority 2030' program, we established the Federal Center for Biotechnology and Medicine Development at our university. This center brings together multiple laboratories working on genetic engineering, targeted drug formulations, and pharmacokinetic studies of new medications. The ongoing research at this facility is a testament to the strong collaboration and scientific excellence of our researchers,» stated Dmitry Glushko, Rector of Ogarev Mordovia State University.

The project is being developed as part of the university’s strategic initiative, «Medicine of the Future: Targeted Pharmacotherapy and Health-Preserving Technologies,» under the Ministry of Science and Higher Education’s «Priority 2030» program, implemented within the framework of the National Project on Science and Universities.